Citadel Advisors’s InflaRx IFRX Stock Holding History

Citadel Advisors’s Portfolio IFRX Stock Details IFRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,200	Closed	-$2.24K	–	13683
2025 Q1	$2.24K	Buy	2,200 +100	+5%	+$189	﹤0.01%	14052
2024 Q4	$5.19K	Buy	+2,100	New	+$4.04K	﹤0.01%	13881
2024 Q1	–	Sell	-5,600	Closed	-$9.13K	–	14978
2023 Q4	$9.13K	Sell	5,600 -2,600	-32%	-$4.46K	﹤0.01%	13172
2023 Q3	$24.4K	Sell	8,200 -13,500	-62%	-$51.4K	﹤0.01%	12458
2023 Q2	$96.8K	Buy	21,700 +20,600	+1,873%	+$92.2K	﹤0.01%	10993
2023 Q1	$2.13K	Sell	1,100 -16,400	-94%	-$35.4K	﹤0.01%	14197
2022 Q4	$54.3K	Buy	+17,500	New	+$44.6K	﹤0.01%	12029
2021 Q3	–	Sell	-10,600	Closed	-$31K	–	14195
2021 Q2	$31K	Buy	+10,600	New	+$35.2K	﹤0.01%	13477

Other funds holding IFRX

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

T3 Companies New York $76.8M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors's IFRX Position: Q1 2026 in Review

Citadel Advisors reduced its InflaRx (IFRX) stake by 58% in Q1 2026, selling an estimated $34.5K and leaving 26,037 shares worth $23.3K. The position accounts for ﹤0.01% of the portfolio, ranked #12635.

Citadel Advisors first reported a position in IFRX in Q1 2018 and has held it in 25 quarters since. The position peaked at $6.13M in Q2 2018. 35 funds tracked by Wall St. Rank hold IFRX as of Q1 2026.

Citadel Advisors held 26,037 shares of InflaRx worth $23.3K as of Q1 2026.
Citadel Advisors sold 36,549 InflaRx shares in Q1 2026, an estimated $34.5K.
InflaRx made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12635 holding.
Citadel Advisors first reported a position in InflaRx in Q1 2018 and has held it in 25 quarters since.
Citadel Advisors's InflaRx position peaked at $6.13M in Q2 2018.
35 funds tracked by Wall St. Rank held InflaRx as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.